2006P-0209 Safety or Efficacy of Diastat (diazepam rectal gel), 5 mg/ml, 10mg/2 ml, 15 mg/3 ml and 20 mg/4 ml
FDA Comment Number : EC5
Submitter : Mr. Dave Lowe Date & Time: 06/27/2006 11:06:42
Organization : Mr. Dave Lowe
Category : Individual Consumer
Issue Areas/Comments
GENERAL
GENERAL
I oppose the petition providing Safety or Efficacy to a rectal gel, and present Depacon for enforcement action. Labeling revised 01/06 misbrands the injection, see attachment. Withdraw any paper that may (or may not have) made that FDA approved. Adequete and well controlled clinical investigations should be the law.

THERE ARE MULTIPLE REPORTS IN THE CLINICAL
LITERATURE WHICH INDICATE THAT THE USE OF
ANTIEPILEPTIC DRUGS DURING PREGNANCY RESULTS IN AN
INCREASED INCIDENCE OF BIRTH DEFECTS IN THE
OFFSPRING. ALTHOUGH DATA ARE MORE EXTENSIVE WITH
RESPECT TO TRIMETHADIONE, PARAMETHADIONE,
PHENYTOIN, AND PHENOBARBITAL, REPORTS INDICATE A
POSSIBLE SIMILAR ASSOCIATION WITH THE USE OF OTHER
ANTIEPILEPTIC DRUGS. THEREFORE, ANTIEPILEPSY DRUGS
SHOULD BE ADMINISTERED TO WOMEN OF CHILDBEARING
POTENTIAL ONLY IF THEY ARE CLEARLY SHOWN TO BE
ESSENTIAL IN THE MANAGEMENT OF THEIR SEIZURES.
THE INCIDENCE OF NEURAL TUBE DEFECTS IN THE FETUS
MAY BE INCREASED IN MOTHERS RECEIVING VALPROATE
DURING THE FIRST TRIMESTER OF PREGNANCY. THE CENTERS
FOR DISEASE CONTROL (CDC) HAS ESTIMATED THE RISK OF
VALPROIC ACID EXPOSED WOMEN HAVING CHILDREN WITH
SPINA BIFIDA TO BE APPROXIMATELY 1 TO 2%.
Animal studies have demonstrated valproate-induced teratogenicity.
Increased frequencies of malformations, as well as intrauterine growth
retardation and death, have been observed in mice, rats, rabbits, and
monkeys following prenatal exposure to valproate. Malformations of the skeletal system are the most common structural abnormalities produced in experimental animals.(See WARNINGS and LOUD SIRENS)
2006P-0209-EC5-Attach-1.PDF